At a glance
ClinicalIndex Comparison RecordN/ACompleted· 207 enrolled
Drug / intervention
DIABE-TEXTdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Feasibility Study Through a Phase II Randomized Clinical Trial of an Intervention Based on Short Message System (SMS) to Promote Adherence to Antidiabetic Medication and Healthy Lifestyles in Patients With Type 2 Diabetes Mellitus
Fundació d'investigació Sanitària de les Illes Balears·interventional·Posted Feb 4, 2021·Updated Feb 28, 2025
In Brief
A clinical study evaluating DIABE-TEXT for Diabetes Mellitus, Type 2. Completed, enrolled 207 participants across 1 site.
Detailed Summary
This study aims at evaluating the feasibility of an intervention based on the use of a mobile-device based system delivering automated, tailored brief text messages to offer support for medicine use and lifestyle recommendations alongside usual care to people with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesSpain
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartDec 2020
First PostedFeb 2021
Primary CompletionApr 2021
Study CompletionJun 2021
TodayJul 2026
First PostedFeb 4, 2021
Enrollment StartDec 30, 2020
Primary CompletionApr 18, 2021
Study CompletionJun 28, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.4 years ago
Interventions
DIABE-TEXTdevice
Participants will receive daily (from monday to friday) text messages in their mobile phones during three months.